BNTC Stock Summary and Trading Ideas (Benitec Biopharma | NASDAQ:BNTC)

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Benitec Biopharma trades on the NASDAQ stock market under the symbol BNTC.

As of February 20, 2026, BNTC stock price declined to $10.64 with 98,031 million shares trading.

BNTC has a beta of 0.58, meaning it tends to be less sensitive to market movements. BNTC has a correlation of 0.02 to the broad based SPY ETF.

BNTC has a market cap of $365.53 million. This is considered a Small Cap stock.

In the last 3 years, BNTC traded as high as $17.15 and as low as $1.86.

The top ETF exchange traded funds that BNTC belongs to (by Net Assets): VTI, IWM, VXF, PINK, IWO.

BNTC has underperformed the market in the last year with a price return of -4.9% while the SPY ETF gained +13.7%. BNTC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.8% and -8.7%, respectively, while the SPY returned +4.3% and +1.7%, respectively.

BNTC support price is $10.37 and resistance is $11.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BNTC shares will trade within this expected range on the day.